RxDoctor Payments Data

Ivan Mefford, MD

Family Medicine · Richmond, TXNPI 1184672404

Payments from drug & device makers

$32,220in general payments, 2019–2025

Across 177 payments — averaging $182.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi US Services Inc.$29K
  • Lilly USA, LLC$360
  • Novo Nordisk$287
  • Pfizer$266
  • AstraZeneca$221
  • AbbVie$219
  • plus $2K from 34 others
$67,110in research payments, 2019–2025

Across 15 payments — averaging $4474.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Sanofi US Services Inc.$67K

What the payments were for

  • Food & beverage$3,16799%
  • Education$221%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$32,220 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$198,725
Medicare patients
545
Services billed
3,200

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide96$111,744
EliquisApixaban115$111,469
JardianceEmpagliflozin91$111,011
TrulicityDulaglutide58$90,098
OtezlaApremilast12$58,033
OzempicSemaglutide42$42,909
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$39,243
JanuviaSitagliptin Phosphate24$25,778
ProliaDenosumab15$25,218
XareltoRivaroxaban17$15,867
FarxigaDapagliflozin Propanediol17$14,313
Janumet XrSitagliptin Phos/Metformin Hcl16$10,380
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog16$8,098
Repatha SureclickEvolocumab12$6,558
Lantus SolostarInsulin Glargine,hum.Rec.Anlog42$6,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$360$201,842154 claims
PfizerEliquis, Premarin, Paxlovid$266$118,681178 claims
Boehringer IngelheimJardiance$60$111,01191 claims
AmgenOtezla, Prolia$202$83,25227 claims
Novo NordiskOzempic$287$42,90942 claims
GSKTrelegy Ellipta$193$39,24353 claims
MerckJanuvia, Janumet Xr$146$36,15840 claims
Johnson & JohnsonXarelto$59$15,86717 claims
AstraZenecaFarxiga$221$14,31317 claims
AbbVieSynthroid$219$2,26358 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Richmond

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →